0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Detection Methods Human Health Effects Remediation Sign in to save

Spray-dried, Biodegradable, Linezolid-loaded Microspheres for Use in the Treatment of Lung Diseases

Journal of Advances in Medical and Pharmaceutical Sciences 2023 1 citation ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count. Score: 40 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Mazen Gharsan Al-Gharsan, Sree Harsha

Summary

This paper is not about microplastics — it describes the development of antibiotic-loaded biodegradable microspheres for inhaled drug delivery to treat lung infections, with no connection to environmental plastic pollution.

Body Systems
Study Type In vivo

Introduction: Researchers worldwide are currently seeking innovative treatment options to combat the alarming increase in bacterial resistance to antimicrobial drugs. Staphylococcus aureus, a frequently encountered and potentially life-threatening bacterium, has become particularly problematic. Linezolid is one of the few medicines on the market that can treat bacteria resistant to other antibiotics. This is the first antibacterial oxazolidinone that has shown to be therapeutically efficacious. Linezolid is a new Oxazolidinone medicine. It kills a broad spectrum of bacteria, including Staphylococcus aureus. Objectives: To reduce non-target organ adverse effects associated with frequent and chronic Linezolid usage, we developed biodegradable, lung-targeted microspheres with sustained release profile. Methods: In this work, a Buchi B-90 nanospray drier was used to prepare a Linezolid-loaded carbopol microsphere (CLSMO)-based formulation. The spray-drying process was optimized using a face-centered central composite design (CCD). Results: The average particle size was 7.516 µm, and the surface of the microspheres was shriveled, according to scanning electron microscope imaging. Drug content and yield were determined to be 73% 3.1% and 72% ± 2.4%., respectively, and drug release (99.1%) peaked for up to 12 hours in vitro. FTIR spectral analysis results suggest that there are no significant physical and chemical interactions between the functional groups of Linezolid and carbopol 934P polymer which ultimately form a stable blend. Linezolid, Carbopol, and CLSMO all had XRD patterns that showed the linezolid would be molecularly dispersed in the polymer. The DSC findings revealed the drug's amorphous nature, which explains the absence of characteristic peaks, indicating a lack of well-defined crystalline structure. Conclusion: The optimized formulation shows significant potential for use as a drug-delivery system in in-vivo applications, particularly in targeted drug delivery to the lungs.

Sign in to start a discussion.

More Papers Like This

Article Tier 2

Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine

This review covers how nanomaterials are being used to improve drug delivery for treating cancer and infections, offering better targeted therapy with fewer side effects. While not directly about microplastics, the research on how nanoparticles interact with human tissues provides insight into how similarly sized nanoplastics might behave once inside the body.

Article Tier 2

Microplastics, potential threat to patients with lung diseases

This review examines the potential threat that airborne microplastics pose to people with existing lung conditions, noting that these particles have been found in human lung tissue and sputum. Researchers explored possible mechanisms by which inhaled microplastics could worsen lung diseases, including triggering inflammation and oxidative stress. The study highlights significant knowledge gaps and calls for more research into how microplastic inhalation affects respiratory health.

Article Tier 2

Microplastics exposed by respiratory tract and exacerbation of community-acquired pneumonia: The potential influences of respiratory microbiota and inflammatory factors

Researchers found that microplastics were present in the lungs of pneumonia patients, and that patients with severe pneumonia had higher levels of microplastics in their airways than those with milder cases. The microplastics appeared to worsen lung infections by disrupting the balance of airway bacteria and increasing inflammation. This study provides early evidence that inhaled microplastics may make respiratory infections more dangerous in humans.

Article Tier 2

Reformulating asthma therapy through nano-phytomedicine: Insights into lung health and microplastic exposure

This review examines the use of nanotechnology-based phytomedicine formulations to improve asthma treatment, while also exploring how microplastic inhalation contributes to lung inflammation and airway dysfunction, framing microplastic exposure as a key driver of rising asthma prevalence.

Article Tier 2

Fabrication of microplastic and nanoplastic particles and fibres for use in pulmonary toxicity studies

Researchers developed fabrication methods for polyamide, polystyrene, and polyethylene terephthalate micro/nanoplastics in both particle and fiber forms, producing respirable-sized test materials with verified chemical purity for use in more environmentally realistic lung toxicity studies.

Share this paper